Citations

Mayo Clinic

Showing 10 of 108135 citations.

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Toft, David O., Ames, Matthew M. , Stensgard, Bridget, Safgren, Stephanie L. , Adjei, Araba A., Sloan, Jeff A. , Atherton, Pamela J. , Vasile, Vlad C. , Salazaar, Sandra, Adjei, Alex A. , Croghan, Gary A., Erlichman, Charles , Goetz, Matthew P. , Reid, Joel M. , Safgren, Stephanie L

Journal of Clinical Oncology | February 18, 2005 | Volume: 23 | Issue: 6 | Pages: 1078-1087

10.1200/jco.2005.09.119 | PMID 15718306 Get It

Purpose We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle in advanced solid tumor patients. We also characterized the pharmacokinetics of 17-AAG, its effect on chaperone and client proteins, and whether cytochrome P450 (CYP) 3A5 and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity. Patients and Methods An accelerated titration design was used. Biomarkers were measured in peripheral-blood mononuclear cells (PBMCs) at baseline and on days 1 and 15, and pharmacokinetic analysis was performed on day 1 of cycle 1. CYP3A5*3 and NQO1*2 genotypes were determined and correlated with pharmacokinetics and toxicity. Results Twenty-one patients received 52 courses at 11 dose levels. DLTs at 431 mg/m2 were grade 3 bilirubin (n = 1), AST (n = 1), anemia (n = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1). No tumor responses were seen. 17-AAG consistently increased heat shock protein (Hsp) 70 levels in PBMCs. At the MTD, the clearance and half-life (t1/2) of 17-AAG were 11.6 L/h/m2 and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t1/2 of 7.63 hours. The CYP3A5*3 and NQO1*2 polymorphisms were not associated with 17-AAG toxicity. The CYP3A5*3 polymorphism was associated with higher 17-AAG clearance. Conclusion The MTD of weekly 17-AAG is 308 mg/m2. 17-AAG induced Hsp70 in PBMCs, indicating that Hsp90 has been affected. Further evaluation of 17-AAG is ongoing using a twice-weekly regimen, and this schedule of 17-AAG is being tested in combination with chemotherapy.
Characterization of Wild-Type and ΔF508 Cystic Fibrosis Transmembrane Regulator in Human Respiratory Epithelia
Kreda, Silvia M. , Mall, Marcus , Mengos, April, Rochelle, Lori G., Yankaskas, James R., Riordan, John R., Boucher, Richard C. , Boucher, Richard C

Molecular Biology of the Cell | February 16, 2005 | Volume: 16 | Issue: 5 | Pages: 2154-2167

10.1091/mbc.e04-11-1010 | PMID 15716351 Get It

Previous studies in native tissues have produced conflicting data on the localization and metabolic fate of WT and ΔF508 cystic fibrosis transmembrane regulator (CFTR) in the lung. Combining immunocytochemical and biochemical studies utilizing new high-affinity CFTR mAbs with ion transport assays, we examined both 1) the cell type and region specific expression of CFTR in normal airways and 2) the metabolic fate of ΔF508 CFTR and associated ERM proteins in the cystic fibrosis lung. Studies of lungs from a large number of normal subjects revealed that WT CFTR protein localized to the apical membrane of ciliated cells within the superficial epithelium and gland ducts. In contrast, other cell types in the superficial, gland acinar, and alveolar epithelia expressed little WT CFTR protein. No ΔF508 CFTR mature protein or function could be detected in airway specimens freshly excised from a large number of ΔF508 homozygous subjects, despite an intact ERM complex. In sum, our data demonstrate that WT CFTR is predominantly expressed in ciliated cells, and ΔF508 CFTR pathogenesis in native tissues, like heterologous cells, reflects loss of normal protein processing.
Assessment of Metabolic Inhibition Potential of Enfuvirtide Using a 5‐Drug Cocktail in HIV‐1 Infected Patients
Patel, Indravadan H., Hawker, Nina, Dorr, Albert, Kolis, Stanley J., Kinchelow, Tosca, Zhang, Xiaoping , Lalezari, Jacob , Badley, Andrew D.

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90658-8 Get It

Clinical Pharmacology & Therapeutics (2003) 73, P81–P81; doi:
Absence of TH1 or TH2 Cytokine Differentiation After Measles Vaccine Virus Immunization Failure
Guerrero, Rubén Bonilla , Dhiman, Neelam , O’Kane, Dennis J., Poland, Gregory A., Jacobson, Robert M.

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90484-x Get It

Clinical Pharmacology & Therapeutics (2003) 73, P35–P35; doi:
Human Catecholamine Sulfotransferase (SULT1A3) Pharmacogenetics: Common Functional Genetic Polymorphism in African‐American Subjects
Thomae, Bianca A., Rifki, Oktay F., Theobald, Michelle A., Eckloff, Bruce W., Wieben, Eric D. , Weinshilboum, R. M.

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90462-0 Get It

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
Thiopurine S‐Methyltransferase (TPMT) Pharmacogenetics: Role of Chaperone Proteins in variant Allozyme Degradation
Wang, L., Sullivan, William J. , Toft, D O, Weinshilboum, Richard

Clinical Pharmacology & Therapeutics | February 16, 2005 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90460-7 Get It

Clinical Pharmacology & Therapeutics (2003) 73, P29–P29; doi:
Microarray Analysis of Genes that Respond to γ-Irradiation in Arabidopsis
Nagata, Toshifumi, Yamada, Hitomi, Du, Zeji , Todoriki, Setsuko, Kikuchi, Shoshi

Journal of Agricultural and Food Chemistry | February 16, 2005 | Volume: 53 | Issue: 4 | Pages: 1022-1030

10.1021/jf0486895 | PMID 15713015 Get It

Early origins of polycystic ovary syndrome
Dumesic, Daniel A. , Schramm, R. Dee, Abbott, David H.

Reproduction, Fertility and Development | February 15, 2005 | Volume: 17 | Issue: 3 | Pages: 349-360

10.1071/rd04092 | PMID 15745643 Get It

The prenatally androgenised female rhesus monkey has become a model for polycystic ovary syndrome (PCOS) in women, with early prenatal androgenisation entraining a permanent PCOS-like phenotype characterised by luteinising hormone (LH) hypersecretion due to reduced hypothalamic sensitivity to steroid negative feedback and relative insulin excess associated with increased abdominal adiposity. These combined reproductive and metabolic abnormalities occur in combination with ovarian hyperandrogenism and follicular arrest in adulthood, and with premature follicle differentiation and impaired embryo development during gonadotrophin therapy for in vitro fertilization (IVF). The ability of prenatal androgen excess in fetal rhesus monkeys to entrain multiple organ systems in utero provides evidence that the hormonal environment of intrauterine life programmes target tissue differentiation, raising the possibility that hyperandrogenism in human fetal development promotes PCOS in adulthood. This hypothesis developed in prenatally androgenised female rhesus monkeys, however, also must include data from clinical studies of PCOS to clarify the homology between human and non-human primates in intrafollicular steroidogenesis and its impact on oocyte developmental competency. By doing so, future studies promise to develop new clinical strategies that will lead to improved pregnancy outcome and reduced pregnancy loss in women with disorders of insulin action, including PCOS, obesity and diabetes mellitus.
Dynamics of Hydrogen−Deuterium Exchange inChlamydomonasCentrin
Ortiz, Mildred, Sanoguet, Zuleika, Hu, Haitao , McMurray, Cynthia T. , Salisbury, Jeffrey L., Pastrana‐Ríos, Belinda , Chazin, Walter

Biochemistry | February 15, 2005 | Volume: 44 | Issue: 7 | Pages: 2409-2418

10.1021/bi0484419 | PMID 15709753 Get It

Application of High Speed Flash Tube to Photographing the Fundus of the Eye in Color
Jacobs, Martin, Ogle, Kenneth N.

Review of Scientific Instruments | February 12, 2005 | Volume: 24 | Issue: 1 | Pages: 52-55

10.1063/1.1770519 Get It

A high speed flash tube is adapted to the Nordensen retinal camera, so that the fundus of the human eye can be photographed in color. The high speed flash eliminates the usually deleterious effect of blinking and eye movements. Special electronic circuits are needed to provide a flickering light from the same flash tube to enable the operator to adjust and focus the camera. Ektachrome film is used and this is over-developed to gain equivalent exposure. For the fundus photographs this apparently results in no loss of color relationships.